Table 1.

Clinical characteristics of control subjects and patients with CRS with NPs.

Characteristics	Control (n = 7)	Non-eosinophilic CRSwNP (n = 12)	Eosinophilic CRSwNP (n = 19)
Age (y), median (range)	41 (28–56)	47 (32–76)	52 (30–71)
Gender (M:F)	6:1	8:4	13:6
Atopy, number (%)	0 (0)	4 (33.3)	11 (57.9)*
Asthma, number (%)	0 (0)	1 (8.3)	3 (15.8)
Aspirin intolerance, number (%)	0 (0)	0 (0)	0 (0)
SNOT-22 score, median (range)	14 (8–32)	40 (16–79)	37 (9–85)
Polyp grade, median (range)	0	3 (3–6)	4 (2–6)
Lund-Mackay CT score, mean ± SD	0	13.4 ± 3.6	17.0 ± 3.4†
E/M ratio, mean ± SD	0	1.6 ± 0.7	2.3 ± 0.8†
Blood eosinophil (cells/μL), median (range)	140 (63–200)	200 (2–462)	279 (89–757)‡
Methodology used, number
Real-time PCR	7	12	19
Tissue homogenate ELISA	7	12	19
Tissue immunohistochemistry	3	12	19

^*P < 0.01, eosinophilic CRSwNP vs. non-eosinophilic CRSwNP, chi-square test.

^†P < 0.01, eosinophilic CRSwNP vs. non-eosinophilic CRSwNP, Mann-Whitney U test.

^‡P < 0.01, eosinophilic CRSwNP vs. controls, Mann-Whitney U test.

SNOT, Sino-nasal outcome test.